Millipore has signed an agreement with Johnson and Johnson Pharmaceutical Research and Development for protein kinase screening using the Upstate KinaseProfiler service
The Upstate KinaseProfiler service is Millipore's 'gold standard' radiometric service.
Under the terms of this agreement, J+JPRD will supply potential protein kinase inhibitors for kinase selectivity profiling against Millipore's panel of 252 protein and lipid kinases.
Millipore's selectivity profiling services help the world's top drug companies evaluate potential leads and guide medicinal chemistry to optimise the most promising compounds and avoid the costly development of non-specific lead candidates.
The panel of kinases assembled for the KinaseProfiler service represents the largest and most disease-relevant of its kind and is under continuous improvement and expansion at Millipore's facility in Dundee, Scotland.
The direct, radiometric assay format used in the KinaseProfiler service assures robust and reliable data that is both reproducible and validated.
Millipore supports the discovery and development of new pharmaceuticals with a portfolio of products and services that expedites the discovery and evaluation of new drug candidates.
This portfolio includes compound screening/profiling capabilities, multiwell filter plates, reagents, immunoassays for key targets and therapeutics categories, and regulatory compliant bioanalytical services for preclinical and clinical trials.
